Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 3/20 | 0.38 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8571208 | 0.99 | KDM1A (0.40) | SLC18A3SIGMAR1TACR1KDM1ACISD1 | |
| SCHEMBL8568450 | 0.92 | KDM1A (0.38) | SLC18A3SIGMAR1TACR1KDM1ACISD1 | |
| SCHEMBL6167647 | 0.91 | SLC6A2 (0.38) | SLC6A2HTR2AHTR2CATMKMT2A | |
| SCHEMBL8562015 | 0.85 | TNKS (0.36) | SLC18A3SIGMAR1KDM1AATMKMT2A | |
| SCHEMBL8564042 | 0.84 | CHRM2 (0.43) | TACR1KDM1AMAOBATMKMT2A | |
| SCHEMBL6168112 | 0.84 | HTR2C (0.50) | HTR2CKMT2AMEN1ALDH1A1 | |
| SCHEMBL8565402 | 0.82 | HTR1A (0.40) | SLC18A3SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL6168606 | 0.81 | OPRL1 (0.52) | KMT2AMEN1 | |
| SCHEMBL29445321 | 0.81 | OPRL1 (0.52) | KMT2AMEN1 | |
| SCHEMBL8564971 | 0.81 | TACR1 (0.43) | TACR1KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329665-B2 | E. g., (+)-3-{1-[3-(2,2,2-trifluoroethoxy)benzyl]piperidin-4-yl}-4-phenyl-3,4dihydro-2(1H)-quinazolinone; pollakiuria and urinary incontinence; anticholinergic agents; selective antagonism of the M3 muscarinic receptor which depresses frequency of rhythmic bladder contractions; side effects reduction | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-02-12 | — | — | US | disclosed |
| EP-1424334-B1 | QUINAZOLINONE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2007-10-24 | — | — | EP | disclosed |
| CN-1307172-C | Quinazolinone derivatives | SUMITOMO PHARMA (JP) | 2007-03-28 | — | — | CN | disclosed |
| EP-1122253-B1 | QUINAZOLINONE DERIVATIVES | SUMITOMO PHARMA (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-20050032819-A1 | Quinazolinone derivative | Sumitomo Pharma Co., Ltd. (JP) | 2005-02-10 | — | — | US | disclosed |
| CN-1538966-A | Quinazolinone derivatives | ס����ҩ��ʽ���� | 2004-10-20 | — | — | CN | disclosed |
| EP-1424334-A1 | QUINAZOLINONE DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-06-02 | — | — | EP | disclosed |
| US-6645971-B1 | Pollakiuria and urinary incontinence treatment; muscarinic receptor antagonists; anticholinergic, anticonvulsants, antiulcer, and antiasthmatics; Parkinson*s disease | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2003-11-11 | — | — | US | disclosed |
| EP-1122253-A1 | QUINAZOLINONE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-08-08 | — | — | EP | disclosed |
| EP-0626373-B1 | Quinazolinone derivatives | SUMITOMO PHARMA (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-5556860-A | ANTIISCHEMIC AGENTS, BRAIN DISORDERS AND BLOOD METAL CONCENTRATIONS AND KIDNEY DISEASE | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0626373-A1 | Quinazolinone derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1994-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032819-A1 | Quinazolinone derivative | CHRM1, CHRM2, CHRM3 | SLC18A3 144/4885SIGMAR1 600/4885TACR1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.